In a significant development for the field of genetic medicine, biotechnology innovators Exegenesis Bio and Modalis Therapeutics have formally announced…
Read More
Breakthrough Micro-Bladder Model Reveals Why UTIs Keep Returning and Points to Phage Therapy as a New Defense
Urinary tract infections (UTIs) are among the most common bacterial ailments treated in clinical practice globally, yet their frustrating tendency…
Read More
Encoded Therapeutics Secures $275M in Series F Financing to Advance Groundbreaking Gene Therapy for Dravet Syndrome and Expand Clinical Pipeline
Encoded Therapeutics has officially closed a massive $275 million Series F financing round, marking a critical financial milestone for the…
Read More
Affinia Therapeutics Secures FDA Orphan Drug Designation for AFTX-201, a Promising Gene Therapy for BAG3-Associated Dilated Cardiomyopathy
Affinia Therapeutics has announced a significant milestone in the development of its investigational gene therapy, AFTX-201, with the US Food…
Read More
Cellares and Papillon Therapeutics Partner to Automate Manufacturing of Investigational Therapy for Friedreich’s Ataxia
In a significant development for the rare disease community, Cellares and Papillon Therapeutics have announced a strategic collaboration aimed at…
Read More
Ludwig Cancer Research Study Identifies Novel Combination Therapy to Overcome Differentiation Blockade in Acute Myelogenous Leukemia
The landscape of hematological oncology is facing a potential paradigm shift following a breakthrough study published in the journal Nature,…
Read More
Breakthrough Combination Therapy Offers New Hope for Acute Myelogenous Leukemia Patients by Overcoming Cellular Differentiation Blocks
In a landmark advancement for hematologic oncology, researchers from Ludwig Cancer Research have unveiled a novel therapeutic strategy targeting acute…
Read More
Ludwig Cancer Research Study Identifies Novel Combination Therapy to Overcome Differentiation Block in Acute Myelogenous Leukemia
Acute Myelogenous Leukemia (AML) remains one of the most formidable challenges in modern oncology, characterized by a rapid progression and…
Read More
Bocunebart’s PACAP-Targeting Mechanism Positions it as a Potential First-in-Class Therapy in a Thin Pipeline of Novel Late-Stage Candidates
New Data Unveiled for Bocunebart, a Promising Migraine Preventive Targeting a Novel Pathway Munich, Germany – June 29, 2026 –…
Read More
Sobi Receives Complete Response Letter from FDA for Investigational Gout Therapy NASP, Focus on Manufacturing Deficiencies
Swedish Orphan Biovitrum (Sobi) has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning…
Read More
